|
Daily Medical Update
Rosacea
Monday, March 16, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
1. Oral JAK Inhibitors as a Promising Therapeutic Strategy for Refractory Rosacea: A Systematic Review and Meta-Analysis
Journal of cosmetic dermatology (2026) - Systematic Review
Key Findings
- Oral JAK inhibitors show pooled response rate of 89.9% in refractory rosacea
- Significant improvements in Investigator's Global Assessment and Clinician's Erythema Assessment
📋 Practice Implication: JAK inhibitors represent a new treatment option for refractory rosacea cases when conventional therapies fail. Should be considered for patients with inadequate response to first-line treatments.
|
2. Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis
Journal of the European Academy of Dermatology and Venereology (2025) - Systematic Review
Key Findings
- Low-dose isotretinoin reduces lesion count and erythema with large effect sizes
- Mean lesion count reduced by 70% and erythema by 47% at 16 weeks post-treatment
📋 Practice Implication: Low-dose isotretinoin is an effective treatment option for rosacea with favorable safety profile. Consider for moderate-to-severe cases, especially when topical therapies fail or for maintenance.
|
3. Efficacy and Safety of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials
JAMA dermatology (2025) - Phase III RCT
Key Findings
- DFD-29 demonstrated superior efficacy vs placebo and doxycycline in IGA success rates
- Mean reduction in total inflammatory lesions was significant vs both comparators
📋 Practice Implication: DFD-29 offers a viable alternative to traditional minocycline and doxycycline for rosacea. May be preferred due to potential reduced adverse effects and convenient once-daily dosing.
|
4. Treatment of redness in rosacea with potassium-titanyl-phosphate (KTP) 532 nm laser with and without topical 1% ivermectin cream
The Journal of dermatological treatment (2026) - RCT
Key Findings
- KTP laser with ivermectin 1% cream showed greater NEI reduction than laser alone (16.6% vs 5.3%)
- Ivermectin combination significantly greater papule reduction across visits
📋 Practice Implication: Combination therapy with KTP laser and topical ivermectin provides superior outcomes for facial erythema in rosacea. Consider for patients seeking non-pharmacological vascular lesion treatment.
|
5. Efficacy and safety of tranilast combined with minocycline in the treatment of moderate-to-severe rosacea
The Journal of dermatological treatment (2026) - RCT
Key Findings
- Combination therapy (tranilast + minocycline) achieved 93.33% IGA success rate vs 46.67% minocycline alone
- Superior outcomes in erythema index, CEA success, and erythema score
📋 Practice Implication: Combination therapy offers superior efficacy for moderate-to-severe rosacea. Tranilast may be considered as an adjunct to standard antibiotics for refractory cases.
|
6. Supramolecular salicylic acid in the treatment of papulopustular rosacea: a multicentre randomized, double-blind, placebo-controlled superiority study
Clinical and experimental dermatology (2025) - Multicenter RCT
Key Findings
- 30% SSA achieved 51.3% efficacy rate vs 18.3% placebo (p < 0.001)
- 59.9% per-protocol efficacy vs 20.5% placebo
📋 Practice Implication: 30% supramolecular salicylic acid offers effective topical treatment for papulopustular rosacea with superior efficacy vs placebo. Good option for patients preferring non-antibiotic topical therapy.
|
|
Today's update reviews newer evidence relevant to Rosacea, with emphasis on what looks actionable in primary care.
|
|